NERA Economic Consulting recently published their annual report examining trends in securities class action litigation in 2021. Although the report found that filings in 2021 decreased overall, the proportion of claims targeting life science firms increased for the second year in a row, following a spike in suits connected to the COVID-19 pandemic.
Latest Post
More Posts
Second Circuit Affirms Dismissal of Action Regarding Clinical Trial Of Macular Degeneration Treatment
S.D.N.Y. Partially Dismisses Claims Against Pharmaceutical Company, But Allows Claim Regarding Misleading Statements About Upcoming NDA for Rare Tissue Disorder To Proceed
S.D.N.Y. Dismisses Action due to Plaintiffs’ Failure to Link Occurrences of Serious Adverse Events to Liver Disease Drug
Subscribe: Subscribe via RSS
Firm/Org